A Cell Cycle Role for the Epigenetic Factor CTCF-L/BORIS

Rosa‐Garrido, Manuel; Ceballos, Laura; Alonso-Lecue, Pilar; Abraira, Cristina; Delgado, M. Dolores; Gandarillas, Alberto

doi:10.1371/journal.pone.0039371

Cited by 36 publications

(36 citation statements)

References 68 publications

(134 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Brother of Regulator of Imprinted Sites ( BORIS ) is the paralogue of CCCTC-binding factor ( CTCF )45. In contrast to CTCF , which is expressed universally in all somatic and germ cells, BORIS is specifically expressed in the embryo, skin, germ cells, and cancer, including colorectal cancer4678910111213. In colorectal cancer, the copy number of BORIS is amplified and BORIS is aberrantly expressed6914, suggesting the potential clinical significance of BORIS in the diagnosis/treatment of colorectal cancer.…”

mentioning

confidence: 99%

Brother of Regulator of Imprinted Sites (BORIS) suppresses apoptosis in colorectal cancer

Zhang

Fang

Song

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Identifying oncogenes that promote cancer cell proliferation or survival is critical for treatment of colorectal cancer. The Brother of Regulator of Imprinted Sites (BORIS) is frequently expressed in most types of cancer, but rarely in normal tissues. Aberrantly expressed BORIS relates to colorectal cancer, but its function in colorectal cancer cells remains unclear. In addition, previous studies indicated the significance of cytoplasm-localized BORIS in cancer cells. However, none of them investigated its function. Herein, we investigated the functions of BORIS in cancer cell proliferation and apoptosis and the role of cytoplasm-localized BORIS in colorectal cancer. BORIS expression correlated with colorectal cancer proliferation. BORIS overexpression promoted colorectal cancer cell growth, whereas BORIS knockdown suppressed cell proliferation. Sensitivity of colorectal cancer cells to 5-fluorouracil (5-FU) was inversely correlated with BORIS expression. These data suggest that BORIS functions as an oncogene in colorectal cancer. BORIS silencing induced reactive oxygen species (ROS) production and apoptosis, whereas BORIS supplementation inhibited apoptosis induced by BORIS short interfering RNA (siRNA), hydrogen peroxide (H2O2) or 5-FU. Introduction of BORIS-ZFdel showed that cytoplasmic localization of BORIS inhibited apoptosis but not ROS production. Our study highlights the anti-apoptotic function of BORIS in colorectal cancer.

show abstract

mentioning

confidence: 99%

Brother of Regulator of Imprinted Sites (BORIS) suppresses apoptosis in colorectal cancer

Zhang

Fang

Song

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…BORIS is expressed in the testis, ovary and skin cells of healthy individuals (13,22). Prior studies have identified the abnormal expression of BORIS in a number of somatic cancer types, including breast cancer and prostate cancer (15)(16)(17)23).…”

Section: Boris Copy Number Alteration In Colorectal Carcinomamentioning

confidence: 99%

Investigation of fusion gene expression in HCT116 cells

et al. 2017

View full text Add to dashboard Cite

Abstract. Colon cancer is the most common type of gastrointestinal cancer. A number of specific and sensitive biomarkers facilitate the diagnosis and monitoring of patients with colon cancer. Fusion genes are typically identified in cancer and a majority of the newly identified fusion genes are oncogenic in nature. Therefore, fusion genes are potential biomarkers and/or therapy targets in cancer. In the present study, the regulation of specific candidate fusion genes were investigated using Brother of the Regulator of Imprinted Sites (BORIS) in the HCT116 colon cancer cell line, which is a paralog of the fusion gene regulator CCCTC-binding factor (CTCF). The copy number of BORIS increased correspondingly to the progression of colorectal carcinoma from the M0 to the M1a stage. It was identified that EIF3E(e1)-RSPO2(e2), EIF3E(e1)-RSPO2(e3), PTPRK(e1)-RSPO3(e2), PTPRK(e7)-RSPO3(e2), TADA2A-MEF2B and MED13L-CD4are fusion transcripts present in the transcriptome of the HCT116 colon cancer cell line. CDC42SE2-KIAAO146 is a genomic fusion transcript, which originates from DNA arrangement in HCT116 cells. BORIS suppresses the expression of EIF3E, RSPO2, PTPRK, RSPO3, TADA2A and CD4 to inhibit the expression of fusion transcripts in HCT116 cells. It was hypothesized that the fusion transcripts investigated in the present study may not be oncogenic in HCT116 cells. As BORIS is not colorectal carcinoma-specific, the fusion genes investigated may be a biomarker assemblage for monitoring the progression of colorectal carcinoma.

show abstract

“…skin, colon, kidney, ovary, fetal tissues, etc.) and non-cancer cells from various origins [4,17,18,46,47,92].…”

Section: Boris Expression In Cancer and Non-cancer Mouse Cellsmentioning

confidence: 99%

“…On the contrary, the expression of BORIS cannot be detected in some cancer cell lines or tumors [10,12,[15][16][17]45,46], and has also been detected in several mouse and human somatic tissues and non-cancerous cell lines [17,46,47]. This may point to the widespread expression of BORIS which is not restricted to cancerous cell lines.…”

Section: Introductionmentioning

confidence: 99%

“…In addition, it has been found that the expression of some CT genes does not rely on the presence of BORIS [12,17,48,49], and thus, it is unlikely that BORIS would be a major CT gene inducing factor [50]. Furthermore, some more general biological functions including a regulatory role in normal cell division have been proposed for BORIS [47], which leads to a significant decrease in cell proliferation and clonogenic capacity. These growth inhibitory functions categorize BORIS as a candidate tumor suppressor gene, rather than an oncogene [20].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Expression analysis of BORIS during pluripotent, differentiated, cancerous, and non-cancerous cell states

Soltanian

Dehghani

Matin

et al. 2014

ABBS

View full text Add to dashboard Cite

BORIS/CTCFL is an 11 zinc finger protein, which is the paralog of CTCF, a ubiquitously expressed protein with diverse roles in gene expression and chromatin organization. Several studies have shown that the expression of BORIS is restricted to normal adult testis, pluripotent cells, and diverse cancer cell lines. Thus, it is known as a cancer-testis (CT) gene that has been hypothesized to exhibit oncogenic properties and to be involved in cancer cell proliferation. On the contrary, other reports have shown that its expression is more widespread and can be detected in differentiated and normal somatic cells; hence, it might have roles in general cellular functions. The present study was aimed to analyze the expression of BORIS in different cell states of pluripotent, differentiated, cancerous and non-cancerous. We found that the two cell states of pluripotency and differentiation are not accompanied with significant variations of BORIS expression. Furthermore, Boris transcripts were detected at approximately the same level in cancer and non-cancer cell lines. These findings suggest that, in contrast to some previous reports, the expression of mouse BORIS is not limited to only cancerous cells or pluripotent cell states.

show abstract

A Cell Cycle Role for the Epigenetic Factor CTCF-L/BORIS

Cited by 36 publications

References 68 publications

Brother of Regulator of Imprinted Sites (BORIS) suppresses apoptosis in colorectal cancer

Brother of Regulator of Imprinted Sites (BORIS) suppresses apoptosis in colorectal cancer

Investigation of fusion gene expression in HCT116 cells

Expression analysis of BORIS during pluripotent, differentiated, cancerous, and non-cancerous cell states

Contact Info

Product

Resources

About